Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.
The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials.
Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupus.
Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features.
Association of IFIH1 and pro-inflammatory mediators: Potential new clues in SLE-associated pathogenesis.
